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Genes to Cells MII et al. multinucleated cells derived from monocyte/macrophage lineage precursor cells that play an essential role in bone resorption (Asagiri & Takayanagi, 2007; Udagawa et al., 1990) . They are also involved in chronic osteolytic diseases, such as osteoporosis, rheumatoid arthritis and periodontitis (Teitelbaum, 2000) .
CD109, a glycosylphosphatidylinositol (GPI)-anchored cell-surface glycoprotein, is a member of the α 2 -macroglobulin/ C3, C4, C5 family of thioester-containing proteins (Lin et al., 2002; Sutherland et al., 1991) . CD109 is a cell-surface antigen expressed on a subset of fetal and adult CD34 + bone marrow mononuclear cells, phytohemagglutinin-activated T lymphoblasts, thrombin-activated platelets, leukemic megakaryoblasts, endothelial cells, mesenchymal stem cell subsets and several types of malignant tumors, such as squamous cell carcinomas (Chuang et al., 2017; Giesert et al., 2003; Hasegawa et al., 2008; Hashimoto et al., 2004; Shiraki et al., 2017; Sunagawa et al., 2016; Yokoyama et al., 2017; Zhang et al., 2015) . Additionally, CD109 was reported to be expressed in the RAW264.7 cell line and in primary monocytes from mouse bone marrow (Wang, Inger, Jiang, Tenenbaum, & Glogauer, 2013) . The same study also found that osteoclast formation decreased in vitro when CD109 expression was suppressed in these cells, suggesting that CD109 plays a role in osteoclastogenesis. In a previous study, we found no obvious physiological abnormalities in CD109-deficient (CD109
−/−
) mice other than psoriasis-like epidermal hyperplasia (Mii et al., 2012) .
Here, we reanalyzed these CD109 −/− mice, focusing on their bones. We showed CD109 expression in osteoblasts as well as osteoclasts in wild-type mice and found, unexpectedly, that CD109 deficiency induces a loss of bone volume in adult mice associated with high bone turnover and a phenotype that resembles type I osteoporosis. These results suggest that CD109 plays a role in bone metabolism in vivo and that CD109 may be a therapeutic target for osteolytic diseases.
| RESULTS

| CD109 deficiency decreased bone volume in adult mice
Observations from plain radiography carried out using a soft X-ray apparatus indicated a lower radiographic density of CD109 −/− femurs as compared with wild-type (CD109
) femurs (Supporting Information Figure S1A and B). This finding prompted us to analyze bone structure in CD109 +/+ and CD109 −/− mice using micro-computed tomography (micro-CT). Three-dimensional micro-CT images of isolated femurs showed a sustained decrease in the number of trabeculae in male CD109 −/− mice compared with male CD109 +/+ mice at 8 and 25 weeks of age (Figure 1a and b) . Quantification of the microstructural parameters of the femurs using micro-CT showed that bone volume/tissue volume (BV/TV) and trabecular number (Tb.N) were significantly decreased and that trabecular separation (Tb. Figure 1d ) but not at 8 weeks (Figure 1c ). Taken together, the reduced BV/TV, decreased Tb.N and relatively preserved Tb.Th along with the decrease in Ct.Th in older mice indicated that CD109 −/− mice exhibited an osteoporosis-like phenotype, which was described in previous papers (Parfitt et al., 1983; Riggs, Khosla, & Melton, 1998; Zebaze et al., 2010) .
| CD109 deficiency induced loss of bone volume with high bone turnover in vivo
To further investigate the bone phenotype of CD109 −/− mice, we evaluated dynamic histomorphometric parameters using double calcein labeling in mice aged 8 weeks (Figure 2 and Supporting Information Figure S2A ). Figure 2d and Supporting Information Figure S2B ). Serum levels of bone alkaline phosphatase (BALP), a marker of bone formation, and N-terminal telopeptide of type 1 collagen (NTx), a marker of bone resorption, were significantly increased in CD109 −/− mice compared with CD109 +/+ mice, whereas there were no significant differences in serum levels of vitamin D 3 , calcium, phosphorus or testosterone between CD109 +/+ and CD109 −/− mice (Supporting Information Figure S2B ). With the exception of the normal testosterone level, this phenotype of CD109 −/− mice is consistent with type I osteoporosis, which is characterized by not only loss of bone volume with high bone turnover, including elevated | Genes to Cells
MAR, BFR/BS, and BALP and NTx serum levels (Eriksen et al., 1990; Riggs, Khosla, Atkinson, Dunstan, & Melton, 2003; Riggs et al., 1998) but also normal serum levels of calcium, phosphorus and vitamin D 3 (Gallagher et al., 1982; Riggs et al., 1998; Sherman, Hollis, & Tobin, 1990) . Although there were no significant differences in osteoid volume/bone volume (OV/BV) and eroded surface/bone surface (ES/BS) ( Figure 2c ), measurements of ES/BS tended to be higher in CD109 −/− mice than in CD109 +/+ mice (p = 0.10; n = 4 per group). These findings suggest that CD109 −/− mice exhibited a mild type I osteoporosis phenotype.
| CD109 was expressed in osteoblasts and osteoclasts in bone
Although CD109 expression has been reported in primary monocytes from mouse bone marrow (Wang et al., 2013) , it remains unclear whether CD109 is expressed in osteoblasts and/or osteoclasts in vivo. We examined CD109 expression in sections of bone from CD109 +/+ and CD109 −/− mice.
Histological and immunohistochemical analyses of the bone sections showed that osteoblasts and osteoclasts from CD109 +/+ mice expressed CD109 protein, but also revealed no apparent histological differences in the osteoblasts and osteoclasts between CD109 +/+ and CD109 −/− mice ( Figure 3a and b), showing comparable size and shape. Similarly, there were no significant differences in the numbers of osteoblasts and osteoclasts between the wild-type and CD109-deficient mice (Figure 3a and b; right graphs) or in the number of osteoclasts measured by histomorphometric analysis (Supporting Information Figure S2A ). The osteoclasts, in particular, were visible as large, multinucleated cells, which were seemingly mature enough to function in CD109 −/− bones ( Figure 3b ); this contradicts a previous report that osteoclast formation in vitro decreased following CD109 suppression (Wang et al., 2013) . We also carried out an osteoclast formation assay, as described in the Supporting Information Appendix S1, and observed reduced osteoclast formation in vitro in primary monocytes from bone marrow of CD109 −/− mice compared with those from CD109 +/+ bone marrow (Figure 3c ). 
F I G U R E 3 Representative histological images of osteoblasts and osteoclasts in bone from
| DISCUSSION
We previously reported that CD109 −/− mice exhibit psoriasislike skin alterations including epithelial hyperplasia with increased basal cell proliferation (Mii et al., 2012) (Miller, Bowman, & Jee, 1995) . A limitation of this study is that we were unable to explain the mechanism by which CD109 deficiency induced the osteoporosis-like phenotype in vivo. Although we tried to explore the mechanism underlying the bone phenotype of CD109 −/− mice by carrying out in vivo experiments, including measurements of serum parameters, there was no significant difference between CD109 +/+ and CD109 −/− mice in serum levels of testosterone, a lack of which is known to play an important role in type I osteoporosis in orchiectomized mice (Bellido et al., 1995) . Additionally, we unexpectedly found that osteoclasts in CD109 −/− bones were large, multinucleated cells that seemingly matured in vivo; this is in contrast to a previous report that osteoclast formation decreases in RAW264.7 cells in vitro when CD109 is suppressed (Wang et al., 2013) . Intriguingly, we observed reduced osteoclast formation in vitro in CD109 −/− mice compared with CD109 +/+ mice (Figure 3c ), supporting the study by Wang et al. (2013) at least for the in vitro component. It remains unclear why we observed contradictory findings between our in vitro and in vivo experiments. Together with previous studies showing that CD109 is a negative regulator of TGF-β signaling (Finnson et al., 2006; Hagiwara et al., 2010; Sunagawa et al., 2016; Zhang et al., 2015) , our hypothesis is that CD109 deficiency induces aberrations in bone metabolism in vivo via TGF-β signaling (Asagiri & Takayanagi, 2007; Edwards et al., 2010; Fennen, Pap, & Dankbar, 2016; Gingery et al., 2008; Itonaga et al., 2004) , whereas CD109 may regulate osteoclastogenesis by a mechanism independent of TGF-β signaling in vitro (Wang et al., 2013) .
In this study, we have reported CD109 expression in osteoblasts and osteoclasts, and showed that CD109 may play a role in bone metabolism in vivo. The discrepancy between our in vitro and in vivo findings might be due to a complex interaction between osteoclasts and osteoblasts. Further investigation is necessary to clarify the mechanism underlying this discrepancy. If the mechanism underlying the function of CD109 in osteoclasts is revealed, CD109 may be a therapeutic target not only for osteolytic diseases but also for metabolic bone disease, including Paget's disease of bone.
| EXPERIMENTAL PROCEDURES
| Mice
CD109
−/− mice were generated as previously described (Mii et al., 2012) and backcrossed onto a C57BL/6J background for 10 generations. Wild-type C57BL/6J mice were purchased from Japan SLC, Inc. (Hamamatsu, Japan). Additionally, wild-type (CD109 +/+ ) siblings of CD109 −/− mice were used as control mice. In this study, male mice were examined to remove the effect of the estrous cycle in female mice. All mice were housed with free access to food and water in polycarbonate cages containing hardwood chip bedding, at 25°C on a 12-hr light-dark cycle in the specific pathogen-free animal facilities of Nagoya University Graduate School of Medicine. Mice were euthanized for blood or tissue collection. The animal experiments in this study were carried out in compliance with the guidelines of Nagoya University Graduate School of Medicine and approved by the Animal Care and Use Committee (Permit Number: 29009).
| Micro-CT
Micro-CT was carried out using a μCT-40 (SCANCO Medical AG, Wangen-Brüttisellen, Switzerland) with a resolution of 12 μm. The three-dimensional microstructural parameters of femurs from 8-week-old mice were calculated as previously described (Ito et al., 2005) . Scores were defined according to the American Society for Bone and Mineral Research standards (Hildebrand, Laib, Müller, Dequeker, & Rüegsegger, 1999) .
| Bone histomorphometry
To assess the dynamic histomorphometric parameters, such as MAR and BFR/BS, calcein (20 mg/kg body weight) was injected twice with a 72-hr interval into CD109 +/+ and CD109 −/− mice. Unilateral femurs of 8-week-old mice were subjected to histomorphometric analysis at Kureha Special Laboratory (Tokyo, Japan). Briefly, bones were fixed with 70% ethanol and embedded in glycol methacrylate. The blocks were cut into 3-μm-thick longitudinal sections using a fully automated rotary microtome (RM2255; Leica Microsystems, Wetzlar, Germany) and stained with toluidine blue (Supporting Information Figure S3 ). In toluidine blue-stained sections, cartilage is stained purple and osteoid is stained blue-gray. The toluidine blue-stained sections and the corresponding fluorescence images (Figure 2b and Supporting Information Figure S3 ) were analyzed as follows: To assess the dynamic histomorphometric parameters, the orthogonal distance between calcein-labeled lines was measured using a fluorescence microscope (BX51, Olympus, Tokyo, Japan). The static and dynamic parameters of trabecular bone were determined in a defined area of the secondary spongiosa between 0.4 and 1.71 mm below the growth plate at 400× magnification, using an Olympus BX51 light microscope and a Histometry RT CAMERA (System Supply, Nagano, Japan) (Supporting Information Figure S3 ). The nomenclature, symbols and units used in this study are those recommended by the Nomenclature Committee of the American Society for Bone and Mineral Research (Parfitt et al., 1987) .
| Blood collection and measurement of serum parameters
Blood samples were collected from the inferior vena cava of mice aged 5 or 8 weeks. BALP was measured at 5 weeks and the other parameters at 8 weeks in this study. The blood was stored for 1 hr at room temperature, and then, the serum was separated by low-speed centrifugation at 1,000 g for 30 min at 4°C. Serum parameters were measured at SRL Inc.
(Tokyo, Japan) as described in the Supporting Information Appendix S1.
| Histological analysis
Mouse bones were fixed in neutral-buffered formalin, decalcified with EDTA, dehydrated and embedded in paraffin. Sections (4 μm) were prepared for hematoxylin and eosin (H&E) staining, immunohistochemistry and tartrate-resistant acid phosphatase (TRAP) staining. Immunohistochemistry was carried out as previously described (Mii et al., 2012) using mouse monoclonal anti-CD109 antibody (Santa Cruz Biotechnology, Dallas, TX, USA) and rabbit polyclonal anti-osteocalcin antibody (EMD Millipore, Billerica, MA, USA). TRAP staining was carried out using a TRAP staining kit (Wako, Osaka, Japan) according to the manufacturer's instructions. The numbers of osteoblasts and osteoclasts per bone perimeter were measured in H&E-stained sections using an Olympus BX53 with a DP73 digital camera and cellSens software (Olympus).
| Statistical analysis
Values are expressed as the mean ± standard deviation. Differences between two groups were analyzed using twotailed Student's t test and Bonferroni's post hoc analysis. A value of p < 0.05 was considered statistically significant.
